We found a match
Your institution may have rights to this item. Sign in to continue.
- Title
Comment on Suissa. Lower Risk of Death With SGLT2 Inhibitors in Observational Studies: Real or Bias? Diabetes Care 2018;41:6-10.
- Authors
Thuresson, Marcus; Cavender, Matthew A.; Fu, Alex Z.; Wilding, John P.; Khunti, Kamlesh; Holl, Reinhard W.; Norhammar, Anna; Birkeland, Kåre I.; Jørgensen, Marit Eika; Wittbrodt, Eric; Hammar, Niklas; Fenici, Peter; Kosiborod, Mikhail; CVD-REAL Investigators and Study Group
- Abstract
The author comments on the study regarding the lower risks of death with sodium-glucose cotransporter 2 inhibitor (SGLT2i) in patients with diabetes. It examines the potential issues on the possibility of immortal time bias that occurs when two patient groups were observed of the methodological approach used in the Comparative Effectiveness of Cardiovascular Outcomes in New Users of SGLT-2 Inhibitors (CVD-REAL) study. The authors agree that such approach could introduce an immortal time bias.
- Subjects
TREATMENT of diabetes; DRUG efficacy; MEDICATION safety; PHARMACOKINETICS; PEOPLE with diabetes
- Publication
Diabetes Care, 2018, Vol 41, Issue 6, pe106
- ISSN
0149-5992
- Publication type
letter
- DOI
10.2337/dc18-0338